Nonoperating Income (Expense) in USD of ELITE PHARMACEUTICALS INC /NV/ from Q2 2010 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).
Summary
ELITE PHARMACEUTICALS INC /NV/ quarterly/annual Nonoperating Income (Expense) history and change rate from Q2 2010 to Q3 2025.
  • ELITE PHARMACEUTICALS INC /NV/ Nonoperating Income (Expense) for the quarter ending 30 Sep 2025 was $7,476,601.000.
  • ELITE PHARMACEUTICALS INC /NV/ Nonoperating Income (Expense) for the twelve months ending 30 Sep 2025 was -$18,419,655.000, a 13.9% increase year-over-year.
  • ELITE PHARMACEUTICALS INC /NV/ annual Nonoperating Income (Expense) for 2024 was -$19,652,608.000, a 90.3% decline from 2023.
  • ELITE PHARMACEUTICALS INC /NV/ annual Nonoperating Income (Expense) for 2023 was -$10,325,677.000, a 3432% decline from 2022.
  • ELITE PHARMACEUTICALS INC /NV/ annual Nonoperating Income (Expense) for 2022 was $309,872.000, a 74.9% decline from 2021.
Nonoperating Income (Expense), Trailing 12 Months (USD)
Nonoperating Income (Expense), Quarterly (USD)
Nonoperating Income (Expense), YoY Quarterly Change (%)
Nonoperating Income (Expense), Annual (USD)
Nonoperating Income (Expense), YoY Annual Change (%)

ELITE PHARMACEUTICALS INC /NV/ Quarterly Nonoperating Income (Expense) (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2025 -$18,419,655 $7,476,601 +$20,480,570 01 Jul 2025 30 Sep 2025 10-Q 14 Nov 2025
Q2 2025 -$38,900,225 -$22,263,921 -$19,247,617 -6.4% 01 Apr 2025 30 Jun 2025 10-Q 14 Aug 2025
Q1 2025 -$19,652,608 $8,118,240 +$9,853,451 01 Jan 2025 31 Mar 2025 10-K 30 Jun 2025
Q4 2024 -$29,506,059 -$11,750,575 -$8,123,660 -2.2% 01 Oct 2024 31 Dec 2024 10-Q 13 Feb 2025
Q3 2024 -$21,382,399 -$13,003,969 -$8,345,681 -1.8% 01 Jul 2024 30 Sep 2024 10-Q 14 Nov 2025
Q2 2024 -$13,036,718 -$3,016,304 -$2,711,041 -8.9% 01 Apr 2024 30 Jun 2024 10-Q 14 Aug 2025
Q1 2024 -$10,325,677 -$1,735,211 -$1,266,047 -2.7% 01 Jan 2024 31 Mar 2024 10-K 30 Jun 2025
Q4 2023 -$9,059,630 -$3,626,915 -$4,677,143 -4.5% 01 Oct 2023 31 Dec 2023 10-Q 13 Feb 2025
Q3 2023 -$4,382,487 -$4,658,288 -$5,103,897 -11.5% 01 Jul 2023 30 Sep 2023 10-Q 14 Nov 2024
Q2 2023 $721,410 -$305,263 +$411,538 +57.4% 01 Apr 2023 30 Jun 2023 10-Q 14 Aug 2024
Q1 2023 $309,872 -$469,164 -$305,789 -1.9% 01 Jan 2023 31 Mar 2023 10-K 01 Jul 2024
Q4 2022 $615,661 $1,050,228 +$598,115 +1.3% 01 Oct 2022 31 Dec 2022 10-Q 14 Feb 2024
Q3 2022 $17,546 $445,609 +$69,238 +18.4% 01 Jul 2022 30 Sep 2022 10-Q 14 Nov 2023
Q2 2022 -$51,692 -$716,801 -$1,285,411 -2.3% 01 Apr 2022 30 Jun 2022 10-Q 14 Aug 2023
Q1 2022 $1,233,719 -$163,375 01 Jan 2022 31 Mar 2022 10-K 29 Jun 2023
Q4 2021 $452,113 -$558,851 -55.3% 01 Oct 2021 31 Dec 2021 10-Q 14 Feb 2023
Q3 2021 $376,371 01 Jul 2021 30 Sep 2021 10-Q 14 Nov 2022
Q2 2021 $568,610 01 Apr 2021 30 Jun 2021 10-Q 15 Aug 2022
Q4 2020 $1,010,964 01 Oct 2020 31 Dec 2020 10-Q 14 Feb 2022
Q1 2018 $4,332,000 -$203,000 -$4,203,000 -1.1% 01 Jan 2018 31 Mar 2018 10-K 14 Jun 2018
Q4 2017 $8,535,000 $517,000 -$1,002,000 -66% 01 Oct 2017 31 Dec 2017 10-K 14 Jun 2018
Q3 2017 $9,537,000 $3,945,000 -$1,498,000 -27.5% 01 Jul 2017 30 Sep 2017 10-K 14 Jun 2018
Q2 2017 $11,035,000 $73,000 -$2,261,000 -96.9% 01 Apr 2017 30 Jun 2017 10-K 14 Jun 2018
Q1 2017 $13,296,000 $4,000,000 -$3,408,000 -46% 01 Jan 2017 31 Mar 2017 10-K 14 Jun 2018
Q4 2016 $16,704,000 $1,519,000 +$11,039,000 01 Oct 2016 31 Dec 2016 10-K 14 Jun 2018
Q3 2016 $5,665,000 $5,443,000 +$3,357,000 +1.6% 01 Jul 2016 30 Sep 2016 10-K 14 Jun 2018
Q2 2016 $2,308,000 $2,334,000 -$4,805,000 -67.3% 01 Apr 2016 30 Jun 2016 10-K 14 Jun 2018
Q1 2016 $7,113,000 $7,408,000 +$8,306,000 01 Jan 2016 31 Mar 2016 10-K 14 Jun 2018
Q4 2015 -$1,193,000 -$9,520,000 -$19,494,000 -2% 01 Oct 2015 31 Dec 2015 10-K 14 Jun 2018
Q3 2015 $18,301,000 $2,086,000 -$8,224,000 -79.8% 01 Jul 2015 30 Sep 2015 10-K 14 Jun 2018
Q2 2015 $26,525,000 $7,139,000 +$4,801,000 +2.1% 01 Apr 2015 30 Jun 2015 10-K 14 Jun 2018
Q1 2015 $21,724,000 -$898,000 +$30,754,000 +97.2% 01 Jan 2015 31 Mar 2015 10-K 14 Jun 2017
Q4 2014 -$9,030,000 $9,974,000 +$9,799,000 +56% 01 Oct 2014 31 Dec 2014 10-K 14 Jun 2017
Q3 2014 -$18,829,000 $10,310,000 +$17,197,000 01 Jul 2014 30 Sep 2014 10-K 14 Jun 2017
Q2 2014 -$36,026,000 $2,338,000 +$243,000 +11.6% 01 Apr 2014 30 Jun 2014 10-K 14 Jun 2017
Q1 2014 -$36,269,000 -$31,652,000 -$33,179,099 -21.7% 01 Jan 2014 31 Mar 2014 10-K 15 Jun 2016
Q4 2013 -$3,089,901 $175,000 -$9,462,376 -98.2% 01 Oct 2013 31 Dec 2013 10-K 15 Jun 2016
Q3 2013 $6,372,475 -$6,887,000 -$8,453,200 -5.4% 01 Jul 2013 30 Sep 2013 10-K 15 Jun 2016
Q2 2013 $14,825,675 $2,095,000 +$12,128,332 01 Apr 2013 30 Jun 2013 10-K 15 Jun 2016
Q1 2013 $2,697,343 $1,527,099 +$8,411,661 01 Jan 2013 31 Mar 2013 10-K 30 Jun 2014
Q4 2012 -$5,714,318 $9,637,376 +$445,431 +4.8% 01 Oct 2012 31 Dec 2012 10-Q 14 Feb 2014
Q3 2012 -$6,159,749 $1,566,200 -$12,944,723 -89.2% 01 Jul 2012 30 Sep 2012 10-Q 14 Nov 2013
Q2 2012 $6,784,974 -$10,033,332 +$20,361,062 +67% 01 Apr 2012 30 Jun 2012 10-Q 14 Aug 2013
Q1 2012 -$13,576,088 -$6,884,562 +$9,299,039 +57.5% 01 Jan 2012 31 Mar 2012 10-K 21 Jun 2013
Q4 2011 -$22,875,127 $9,191,945 +$3,335,602 +57% 01 Oct 2011 31 Dec 2011 10-Q 14 Feb 2013
Q3 2011 -$26,210,729 $14,510,923 +$12,508,852 +6.2% 01 Jul 2011 30 Sep 2011 10-Q 14 Nov 2012
Q2 2011 -$38,719,581 -$30,394,394 -$25,721,769 -5.5% 01 Apr 2011 30 Jun 2011 10-Q 14 Aug 2012
Q1 2011 -$12,997,812 -$16,183,601 01 Jan 2011 31 Mar 2011 10-K 29 Jun 2012
Q4 2010 $5,856,343 01 Oct 2010 31 Dec 2010 10-Q 14 Feb 2012
Q3 2010 $2,002,071 01 Jul 2010 30 Sep 2010 10-Q 14 Nov 2011
Q2 2010 -$4,672,625 01 Apr 2010 30 Jun 2010 10-Q/A 19 Aug 2011

ELITE PHARMACEUTICALS INC /NV/ Annual Nonoperating Income (Expense) (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 -$19,652,608 -$9,326,931 -90.3% 01 Apr 2024 31 Mar 2025 10-K 30 Jun 2025
2023 -$10,325,677 -$10,635,549 -34.3% 01 Apr 2023 31 Mar 2024 10-K 30 Jun 2025
2022 $309,872 -$923,847 -74.9% 01 Apr 2022 31 Mar 2023 10-K 01 Jul 2024
2021 $1,233,719 -$806,272 -39.5% 01 Apr 2021 31 Mar 2022 10-K 29 Jun 2023
2020 $2,039,991 01 Apr 2020 31 Mar 2021 10-K 29 Jun 2022
2015 $7,113,336 -$14,610,992 -67.3% 01 Apr 2015 31 Mar 2016 10-K 15 Jun 2016
2014 $21,724,328 +$57,994,212 01 Apr 2014 31 Mar 2015 10-K 15 Jun 2016
2013 -$36,269,884 -$38,967,227 -14.4% 01 Apr 2013 31 Mar 2014 10-K 15 Jun 2016
2012 $2,697,343 +$16,273,431 01 Apr 2012 31 Mar 2013 10-K 30 Jun 2014
2011 -$13,576,088 -$578,276 -4.4% 01 Apr 2011 31 Mar 2012 10-K 21 Jun 2013
2010 -$12,997,812 01 Apr 2010 31 Mar 2011 10-K 29 Jun 2012
* An asterisk sign (*) next to the value indicates that the value is likely invalid.